Skip to main content
. 2017 Apr 27;1(1):111–116. doi: 10.1016/j.mayocpiqo.2017.04.003

Figure 4.

Figure 4

Noninvasive detection and monitoring of ctDNA using targeted NGS. Dynamic changes in tumor burden (A) and carcinoembryonic antigen (B) in response to crizotinib treatment were closely correlated with alterations in fractional abundance of STRN-ALK in plasma. C, Concordance between different reporters (SNVs and fusion) in response to crizotinib. APC = adenomatous polyposis coli; CEA = carcinoembryonic antigen; ctDNA = circulating tumor DNA; MAF = mutant allele frequency; MAP2K1 = mitogen-activated protein kinase kinase 1; NGS = next-generation sequencing; SNV = single nucleotide variant; STAT3 = signal transducer and activator of transcription 3; TP53 = tumor protein 53.